Skip to main content
Top
Published in: Journal of Infection and Chemotherapy 6/2010

01-12-2010 | Original Article

Complement-mediated bacteriolysis after binding of specific antibodies to drug-resistant Pseudomonas aeruginosa: morphological changes observed by using a field emission scanning electron microscope

Authors: Jun Tanaka, Takashi Nakae, Takatoshi Onoe, Yoshitaka Horiuchi, Hiroyoshi Miyamoto, Jun Adan-Kubo, Hiroaki Adachi, Yasuo Ono

Published in: Journal of Infection and Chemotherapy | Issue 6/2010

Login to get access

Abstract

A bactericidal mechanism mediated by human serum was investigated by a field emission scanning electron microscope and a strain of drug-resistant Pseudomonas aeruginosa. When the bacteria were treated with meropenem, a carbapenem antibiotic, spheroplasts and bulges (spheroidization) appeared after 1–3 h. When 40% serum was added to the bacteria, the bacteria agglutinated within 2 min and then lysed after 5–30 min. Immunoelectron micrographic analyses showed dispositions of complement component C9 molecules on the cell surface of lysed bacteria by the serum treatment that might suggest formation of a membrane attack complex. Immunoglobulin G (IgG) depletion from the serum diminished the lytic activity and adding human intravenous immunoglobulin (IVIG) restored it, suggesting that lysis was induced by specific IgG binding to the bacteria. IVIG may help patients with less IgG against bacteria to overcome severe infection.
Literature
1.
go back to reference National Nosocomial Infection Surveillance System. National nosocomial infection surveillance (NNIS) system report: data summary from January 1992 through June 2004. Am J Infect Control. 2004;32:470–85.CrossRef National Nosocomial Infection Surveillance System. National nosocomial infection surveillance (NNIS) system report: data summary from January 1992 through June 2004. Am J Infect Control. 2004;32:470–85.CrossRef
2.
go back to reference Nouer SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother. 2005;49:3663–7.PubMedCrossRef Nouer SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother. 2005;49:3663–7.PubMedCrossRef
3.
go back to reference Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50:43–8.PubMedCrossRef Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50:43–8.PubMedCrossRef
4.
go back to reference Mikolajczyk MG, Concepcion NF, Wang T, Fraizer D, Golding B, Frasch CE, et al. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol. 2004;11:1158–64.PubMed Mikolajczyk MG, Concepcion NF, Wang T, Fraizer D, Golding B, Frasch CE, et al. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol. 2004;11:1158–64.PubMed
5.
go back to reference Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983;147:1090–8.PubMed Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983;147:1090–8.PubMed
6.
go back to reference Nakae T, Hirayama F, Hashimoto M. Neutralizing activity of human immunoglobulin preparation against toxic shock syndrome toxin-1. Kansenshogaku Zasshi. 2002;76:195–202.PubMed Nakae T, Hirayama F, Hashimoto M. Neutralizing activity of human immunoglobulin preparation against toxic shock syndrome toxin-1. Kansenshogaku Zasshi. 2002;76:195–202.PubMed
7.
go back to reference Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis. 1998;26:631–8.PubMedCrossRef Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis. 1998;26:631–8.PubMedCrossRef
8.
go back to reference Yanagisawa C, Hanaki H, Natae T, Sunakawa K. Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother. 2007;13:368–72.PubMedCrossRef Yanagisawa C, Hanaki H, Natae T, Sunakawa K. Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother. 2007;13:368–72.PubMedCrossRef
9.
go back to reference Masaoka T, Hasegawa H, Takaku F, Mizoguchi H, Asano S, Ikeda Y, et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother. 2000;48:199–217. Masaoka T, Hasegawa H, Takaku F, Mizoguchi H, Asano S, Ikeda Y, et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother. 2000;48:199–217.
10.
go back to reference Ono Y, Ito T, Watanabe T, Koshio O, Tansho S, Ikeda T, et al. Opsonic activity assessment of human intravenous immunoglobulin preparations against drug-resistant bacteria. J Infect Chemother. 2004;10:234–8.PubMed Ono Y, Ito T, Watanabe T, Koshio O, Tansho S, Ikeda T, et al. Opsonic activity assessment of human intravenous immunoglobulin preparations against drug-resistant bacteria. J Infect Chemother. 2004;10:234–8.PubMed
11.
go back to reference Nakae T, Tanaka J, Nakano A, Ono Y. Complement-mediated bactericidal effect of antibodies in human intravenous preparation against multi-drug resistant Pseudomonas aeruginosa. Jpn J Antibiot. 2008;61:379–87.PubMedCrossRef Nakae T, Tanaka J, Nakano A, Ono Y. Complement-mediated bactericidal effect of antibodies in human intravenous preparation against multi-drug resistant Pseudomonas aeruginosa. Jpn J Antibiot. 2008;61:379–87.PubMedCrossRef
12.
go back to reference Fujita M, Matsushita M, Endo Y. The lectin-complement pathway: its role in innate immunity and evolution. Immunol Rev. 2004;198:185–202.PubMedCrossRef Fujita M, Matsushita M, Endo Y. The lectin-complement pathway: its role in innate immunity and evolution. Immunol Rev. 2004;198:185–202.PubMedCrossRef
13.
go back to reference Mastellos D, Morikis D, Isaacs SN, Holland MC, Strey CW, Lambris JD. Complement: structure, functions, evolution, and viral molecular mimicry. Immunol Res. 2003;27:367–86.PubMedCrossRef Mastellos D, Morikis D, Isaacs SN, Holland MC, Strey CW, Lambris JD. Complement: structure, functions, evolution, and viral molecular mimicry. Immunol Res. 2003;27:367–86.PubMedCrossRef
14.
go back to reference Rosado CJ, Buckle AM, Law RH, Butcher RE, Kan WT, Bird CH, et al. A common fold mediates vertebrate defense and bacterial attack. Science. 2007;317:1548–51.PubMedCrossRef Rosado CJ, Buckle AM, Law RH, Butcher RE, Kan WT, Bird CH, et al. A common fold mediates vertebrate defense and bacterial attack. Science. 2007;317:1548–51.PubMedCrossRef
15.
go back to reference Tschopp J, Masson D, Stanley KK. Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature (Lond). 1986;322:831–4.CrossRef Tschopp J, Masson D, Stanley KK. Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature (Lond). 1986;322:831–4.CrossRef
16.
go back to reference DiScipio RG, Hugli TE. The architecture of complement component C9 and poly(C9). J Biol Chem. 1985;260:14802–9.PubMed DiScipio RG, Hugli TE. The architecture of complement component C9 and poly(C9). J Biol Chem. 1985;260:14802–9.PubMed
17.
go back to reference DiScipio RG, Berlin C. The architectural transition of human complement component C9 to poly(C9). Mol Immunol. 1999;36:575–85.PubMedCrossRef DiScipio RG, Berlin C. The architectural transition of human complement component C9 to poly(C9). Mol Immunol. 1999;36:575–85.PubMedCrossRef
18.
go back to reference Nusinow SR, Zuraw BL, Curd JG. The hereditary and acquired deficiencies of complement. Med Clin N Am. 1985;69:487–504.PubMed Nusinow SR, Zuraw BL, Curd JG. The hereditary and acquired deficiencies of complement. Med Clin N Am. 1985;69:487–504.PubMed
19.
go back to reference Trautmann M, Heinemann M, Zick R, Möricke A, Seidelmann M, Berger D. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Eur J Clin Microbiol Infect Dis. 1998;17:754–60.PubMedCrossRef Trautmann M, Heinemann M, Zick R, Möricke A, Seidelmann M, Berger D. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Eur J Clin Microbiol Infect Dis. 1998;17:754–60.PubMedCrossRef
20.
go back to reference Horii T, Kobayashi M, Sato K, Ichiyama S, Ohta M. An in vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli. J Antimicrob Chemother. 1998;41:435–42.PubMedCrossRef Horii T, Kobayashi M, Sato K, Ichiyama S, Ohta M. An in vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli. J Antimicrob Chemother. 1998;41:435–42.PubMedCrossRef
21.
go back to reference Sumita Y, Tada S, Nouda H, Okuda T, Fukasawa M. Mode of action of Meropenem, a new carbapenem antibiotic. Chemotherapy 1992;40 Suppl 1:90–102. Sumita Y, Tada S, Nouda H, Okuda T, Fukasawa M. Mode of action of Meropenem, a new carbapenem antibiotic. Chemotherapy 1992;40 Suppl 1:90–102.
22.
go back to reference Tschopp J, Engel A, Podack ER. Molecular weight of poly(C9): 12 to 18 C9 molecules form the transmembrane channel of complement. J Biol Chem. 1984;259:1922–8.PubMed Tschopp J, Engel A, Podack ER. Molecular weight of poly(C9): 12 to 18 C9 molecules form the transmembrane channel of complement. J Biol Chem. 1984;259:1922–8.PubMed
23.
go back to reference Skansén-Saphir U, Andersson J, Björk L, Ekberg C, Fehniger TE, Henter JI, et al. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand J Immunol. 1998;47:229–35.PubMedCrossRef Skansén-Saphir U, Andersson J, Björk L, Ekberg C, Fehniger TE, Henter JI, et al. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand J Immunol. 1998;47:229–35.PubMedCrossRef
24.
go back to reference Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect. 2004;57:112–8.PubMedCrossRef Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect. 2004;57:112–8.PubMedCrossRef
Metadata
Title
Complement-mediated bacteriolysis after binding of specific antibodies to drug-resistant Pseudomonas aeruginosa: morphological changes observed by using a field emission scanning electron microscope
Authors
Jun Tanaka
Takashi Nakae
Takatoshi Onoe
Yoshitaka Horiuchi
Hiroyoshi Miyamoto
Jun Adan-Kubo
Hiroaki Adachi
Yasuo Ono
Publication date
01-12-2010
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 6/2010
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-010-0074-4

Other articles of this Issue 6/2010

Journal of Infection and Chemotherapy 6/2010 Go to the issue

Acknowledgment to Reviewers

Acknowledgments